Add a bookmark to get started

19 May 20231 minute read

Life sciences companies and the risks posed by the mifepristone litigation

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

Listen to the At the Intersection of Science and Law podcast on iTunes and Spotify.